# A Study to Evaluate if AC-084 is Safe, Its Fate in the Body as Well as Its Potential Effects on the Body in Healthy Subjects

> **NCT02905253** · PHASE1 · TERMINATED · sponsor: **Idorsia Pharmaceuticals Ltd.** · enrollment: 56 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** AC-084
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02905253
- **Lead sponsor:** Idorsia Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-09-12
- **Primary completion:** 2017-12-10
- **Final completion:** 2017-12-10
- **Target enrollment:** 56 (ACTUAL)
- **Why stopped:** The study has been terminated due to difficulties in recruiting subjects into Part C. No safety concerns contributed to the termination of the study
- **Last updated:** 2018-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02905253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02905253, "A Study to Evaluate if AC-084 is Safe, Its Fate in the Body as Well as Its Potential Effects on the Body in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02905253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*